Limits...
Comparison of drug coverage in Canada before and after the establishment of the pan-Canadian Pharmaceutical Alliance.

Milliken D, Venkatesh J, Yu R, Su Z, Thompson M, Eurich D - BMJ Open (2015)

Bottom Line: Comparison of the pCPA era group to the pre-pCPA era group indicated that the proportion listed did not change significantly in any jurisdiction, and time-to-listing increased significantly in New Brunswick and decreased significantly in Alberta, Manitoba, and Ontario.When the pCPA negotiation subgroup was compared to the pre-pCPA era group, the proportion listed increased significantly in British Columbia, Saskatchewan, Manitoba and Newfoundland and Labrador, and time-to-listing increased significantly in New Brunswick and Nova Scotia and decreased significantly in Manitoba and Ontario.While the pCPA might have had a varied effect on time-to-listing, this study's primary analysis did not observe a significant impact on the overall proportion of new drug indications listed across jurisdictions.

View Article: PubMed Central - PubMed

Affiliation: MILLREED Enterprises Ltd, Toronto, Ontario, Canada.

No MeSH data available.


Related in: MedlinePlus

Change in median time-to-listing before and after the establishment of the pCPA. Notes: Lighter columns=pCPA era group − pre-pCPA era group; darker columns=pCPA negotiation subgroup − pre-pCPA era group; refer to the Methods section for the groups’ definitions. pCPA, pan-Canadian Pricing Alliance. *Change in time-to-listing is significant as per the Mann–Whitney U test (p<0.05).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4563252&req=5

BMJOPEN2015008100F1: Change in median time-to-listing before and after the establishment of the pCPA. Notes: Lighter columns=pCPA era group − pre-pCPA era group; darker columns=pCPA negotiation subgroup − pre-pCPA era group; refer to the Methods section for the groups’ definitions. pCPA, pan-Canadian Pricing Alliance. *Change in time-to-listing is significant as per the Mann–Whitney U test (p<0.05).

Mentions: Across the jurisdictions, the range of the median time-to-listing for listed drug indications was 140–719 calendar days in the pre-pCPA era group, 131–457 days in the pCPA era group and 139–390 days in the pCPA negotiation subgroup (table 1). In the primary analysis comparing the pCPA era group to the pre-pCPA era group, the change in the median time-to-listing ranged from a decrease of 360 days in Manitoba to an increase of 88 days in New Brunswick and Newfoundland and Labrador (figure 1). Further, time-to-listing increased significantly in New Brunswick and decreased significantly in Alberta, Manitoba and Ontario (table 1). In the subgroup analysis which compared the pCPA negotiation subgroup to the pre-pCPA era group, the change in the median time-to-listing ranged from a decrease of 337 days in Prince Edward Island to an increase of 165 days in Newfoundland and Labrador (figure 1). For this comparison, time-to-listing increased significantly in New Brunswick and Nova Scotia and decreased significantly in Manitoba and Ontario (table 1).


Comparison of drug coverage in Canada before and after the establishment of the pan-Canadian Pharmaceutical Alliance.

Milliken D, Venkatesh J, Yu R, Su Z, Thompson M, Eurich D - BMJ Open (2015)

Change in median time-to-listing before and after the establishment of the pCPA. Notes: Lighter columns=pCPA era group − pre-pCPA era group; darker columns=pCPA negotiation subgroup − pre-pCPA era group; refer to the Methods section for the groups’ definitions. pCPA, pan-Canadian Pricing Alliance. *Change in time-to-listing is significant as per the Mann–Whitney U test (p<0.05).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4563252&req=5

BMJOPEN2015008100F1: Change in median time-to-listing before and after the establishment of the pCPA. Notes: Lighter columns=pCPA era group − pre-pCPA era group; darker columns=pCPA negotiation subgroup − pre-pCPA era group; refer to the Methods section for the groups’ definitions. pCPA, pan-Canadian Pricing Alliance. *Change in time-to-listing is significant as per the Mann–Whitney U test (p<0.05).
Mentions: Across the jurisdictions, the range of the median time-to-listing for listed drug indications was 140–719 calendar days in the pre-pCPA era group, 131–457 days in the pCPA era group and 139–390 days in the pCPA negotiation subgroup (table 1). In the primary analysis comparing the pCPA era group to the pre-pCPA era group, the change in the median time-to-listing ranged from a decrease of 360 days in Manitoba to an increase of 88 days in New Brunswick and Newfoundland and Labrador (figure 1). Further, time-to-listing increased significantly in New Brunswick and decreased significantly in Alberta, Manitoba and Ontario (table 1). In the subgroup analysis which compared the pCPA negotiation subgroup to the pre-pCPA era group, the change in the median time-to-listing ranged from a decrease of 337 days in Prince Edward Island to an increase of 165 days in Newfoundland and Labrador (figure 1). For this comparison, time-to-listing increased significantly in New Brunswick and Nova Scotia and decreased significantly in Manitoba and Ontario (table 1).

Bottom Line: Comparison of the pCPA era group to the pre-pCPA era group indicated that the proportion listed did not change significantly in any jurisdiction, and time-to-listing increased significantly in New Brunswick and decreased significantly in Alberta, Manitoba, and Ontario.When the pCPA negotiation subgroup was compared to the pre-pCPA era group, the proportion listed increased significantly in British Columbia, Saskatchewan, Manitoba and Newfoundland and Labrador, and time-to-listing increased significantly in New Brunswick and Nova Scotia and decreased significantly in Manitoba and Ontario.While the pCPA might have had a varied effect on time-to-listing, this study's primary analysis did not observe a significant impact on the overall proportion of new drug indications listed across jurisdictions.

View Article: PubMed Central - PubMed

Affiliation: MILLREED Enterprises Ltd, Toronto, Ontario, Canada.

No MeSH data available.


Related in: MedlinePlus